In the article "Pegylated Interferon and Ribavirin-Induced Depression in Chronic Hepatitis C: Role of Personality" by Pere Castellvi, BS, and colleagues in the June 2009 issue (), the institutional affiliation of Mr Castellvi and Dr Subir× —Universitat Aut×²noma de Barcelona—was omitted.
In the article "Extended Release Quetiapine Fumarate Monotherapy in Major Depressive Disorder: A Placebo- and Duloxetine-Controlled Study" by Andrew J. Cutler, MD, and colleagues in the April 2009 issue (), an error was made in the exclusion criteria. The text "if the current episode was associated with psychotic features" should be deleted in the second paragraph of the subsection "Patient Population" (p 527) in the Method.
In the article "The Safety of Olanzapine in Adolescents With Schizophrenia or Bipolar I Disorder: A Pooled Analysis of 4 Clinical Trials" by Ludmila A. Kryzhanovskaya, MD, PhD, and colleagues in the February 2009 issue (), the text on page 255 (right column, lines 32-35) regarding mean changes in fasting glucose and triglycerides in adolescents versus adults is in error. The corrected statement reads:
Unlike with weight gain, however, adolescents had significantly smaller mean changes in fasting glucose during olanzapine treatment compared with those of adults; adults had smaller mean changes in fasting triglycerides and a greater incidence of abnormal changes from normal to high glucose, total cholesterol, LDL cholesterol, and triglycerides at anytime during treatment.
In the article "Duloxetine in the Prevention of Depressive Recurrences: A Randomized, Double-Blind, Placebo-Controlled Trial" by David G. S. Perahia, MD, and colleagues in the May 2009 issue (Figure 4 on page 711.), a single asterisk was missing for the duloxetine group at week 52 in
The online articles at Psychiatrist.com have been corrected.
© Copyright 2009 Physicians Postgraduate Press, Inc.